Back to results
US 12,173,063 B2Granted
Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
AssigneeAvenCell Europe GmbH
InventorArmin Ehninger
Life of this patent
Estimating the term…
Abstract
The present invention relates to a targeting module comprising a chemically synthesized peptide binding moiety specific for a human cell surface protein or protein complex, a kit comprising the targeting module and a vector or a cell comprising a nucleic acid encoding a universal chimeric antigen receptor and the use for the treatment of cancer, infections and autoimmune disorders.
Claims14
A targeting module comprising
- a tag, wherein the tag is a peptide according to SEQ ID NO:
- 25 or SEQ ID NO:
- 27, and
- a chemically synthesized peptide binding moiety that comprises somatostatin, a somatostatin analogue, a somatostatin antagonist, bombesin, a bombesin analogue, gastrin-releasing peptide (GRP), a GRP analogue, neuromedin B, a neuromedin B analogue, a peptide from the vasoactive secretin family, a glutamate-urea-lysine motif, a melanocyte-stimulating hormone (MSH), a MSH analogue, a cholecystokinin (CCK), a gastrin, neurotensin, a neurotensin analogue, a peptide from the gonadotropin-releasing hormone family, a neurokine, an exendin, an exenatide, an Arg-Gly-Asp (RGD) peptide, an Asn-Gly-Arg (NGR) peptide, a neuregulin, or wherein the chemically synthesized peptide binding moiety has binding specificity to a membrane receptor.
1 more element
Dependencies are inferred from the claim text.